Pharmaceutical companies Nektar Therapeutics and Bristol-Myers Squibb have expanded their collaboration to develop an anti-cancer treatment.
The treatment comprises Nektar’s bempegaldesleukin (bempeg) and Bristol-Myers' Opdivo (nivolumab). The expansion would go beyond the three pivotal studies in first-line metastatic melanoma, first-line cisplatin-ineligible metastatic urothelial cancer and first-line metastatic renal cell carcinoma (RCC) - to include additional trials in adjuvant melanoma and in muscle-invasive bladder cancer. Nektar and Bristol-Myers will also begin phase 1/2 dose escalation studies in first-line RCC.
The two companies began the partnership in 2016. The cost-sharing conditions won’t change in the expanded accord.
Bristol-Myers will also fund a Phase 1/2 dose optimization and expansion trial assessing the combo in first-line non-small cell lung cancer.
Nektar will be able to receive up to $125 million total once the first patients are dosed in the adjuvant melanoma trial ($25 million), muscle-invasive bladder cancer trial ($25 million), and NSCLC trial ($75 million).
NKTR moved above its 50-day moving average on June 24, 2025 date and that indicates a change from a downward trend to an upward trend. In of 41 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for NKTR just turned positive on June 24, 2025. Looking at past instances where NKTR's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
The 10-day moving average for NKTR crossed bullishly above the 50-day moving average on June 24, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where NKTR advanced for three days, in of 225 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 118 cases where NKTR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for NKTR moved out of overbought territory on July 03, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 09, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NKTR as a result. In of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NKTR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
NKTR broke above its upper Bollinger Band on June 24, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NKTR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (31.447) is normal, around the industry mean (17.292). P/E Ratio (0.000) is within average values for comparable stocks, (58.926). NKTR's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.456). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (4.008) is also within normal values, averaging (271.367).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NKTR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of inhalation drug delivery systems
Industry Biotechnology